胃癌组织HER-2基因的检测用于靶向治疗

Evaluation of HER- 2 gene status in gastric cancer can be used for molecular targeted therapy

目的荧光原位杂交(FISH)法与免疫组织化学(IHC)染色法检测胃癌组织HER-2基因状态,用于靶向治疗。方法应用FISH法检测77例IHC染色法CerbB-2蛋白表达为(2+)及(3+)的胃腺癌标本中HER-2基因扩增情况。结果 FISH结果,22例HER(3+)标本中,17例存在HER-2基因扩增,符合率77.3%:5例阴性病例中2例为多倍体,占40%。55例HER-2(2+)的病例中,9例(16.3%)存在HER-2基因扩增,46例阴性病例中19例为多倍体,占41.3%。结论对于IHC筛查HER-2(3+)及HER-2(2+)拟行靶向治疗的病例明确HER2基因状态,需进一步行FISH检测,同时要考虑l7号染色体多体的影响。

Objective To detect HER- 2 /neu gene status in gastric cancer by immunohistochemistry（IHC） and fluorescence in situhybridization（FISH）. This can be used for molecular targeted therapy. Methods CerbB- 2 protein expression was examined by FISH in IHC HER- 2（2 ＋） and（3 ＋） of 77 gastric adenocarcinoma specimens. Results There are 17 cases of gene amplification in 22 HER- 2（3 ＋） specimens（77. 3%）,and in 5 cases of HER- 2（3 ＋）specimens without gene amplification,2（40%） cases of chromosome 17 polyploid were detected. However,there are only 9 cases of gene Amplification in 55 HER- 2（2 ＋）specimens（16. 3%）,and in 46 cases of HER- 2（2 ＋）specimens without gene amplification,19 of 46 cases of chromosome 17 polyploidy were detected. Conclusion HER- 2（3 ＋） and HER- 2（2 ＋） initial detection cases should be further detected by FISH to analyze HER- 2 gene status. Chromosome17 polyploid should be considered in the evaluation of HER- 2 gene status.